However, the predominant background treatment was metformin, used either as monotherapy or in combination with other medications
According to FDA labeling and clinical trials, HbA1c reductions of 1.01.5% are common in patients with type 2 diabetes, though the exact reduction varies by baseline A1c, dose, and individual response
However, uncertainties remain regarding the full extent of health benefits, real-world adherence and potential pricing changes
The scope of this NMA was to compare the effectiveness of OMMs for the treatment of obesity and obesity-related complications
doi: 10.1186/s13195-024-01666-7
Youll receive honest advice, clear aftercare guidance and a clean, clinical setting for your treatment